SLRX - Salarius Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.6700
+0.0500 (+8.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.6200
Open0.6457
Bid0.5800 x 900
Ask0.6900 x 1300
Day's Range0.6050 - 0.6980
52 Week Range0.5550 - 24.4500
Volume96,401
Avg. Volume298,858
Market Cap9.157M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.1220
Earnings DateApr 28, 2020 - May 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
  • Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results
    GlobeNewswire

    Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

    Seclidemstat Achieves Dose-Escalation Milestone in Phase 1/2 Ewing Sarcoma Clinical Trial Sixth Level Dosing Cohort Now Proceeding; On Track To Report Topline Data in 2020.

  • Salarius Announces Allowance of New European Patent Covering Seclidemstat
    GlobeNewswire

    Salarius Announces Allowance of New European Patent Covering Seclidemstat

    European Patent Office Satisfied Patent Application Meets All Requirements Salarius’ Global Intellectual Property Estate Includes 22 Issued Patents in the U.S., Europe and 12.

  • Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference
    GlobeNewswire

    Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today that its chief executive officer, David Arthur, will be attending the 30th Annual Oppenheimer Healthcare Conference being held in New York City. The Oppenheimer Healthcare Conference brings together a broad spectrum of public and private healthcare companies, spanning all major sectors of the healthcare sector. Mr. Arthur will provide a corporate update highlighting recent achievements, upcoming clinical milestones and its focus on developing epigenetic-based therapies for rare and hard-to-treat cancers.

  • Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
    GlobeNewswire

    Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the closing of its previously announced underwritten public offering, with total gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius. The offering is comprised of 7,101,307 Class A Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $1.15 per share, and 1,246,519 Class B Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of Series A convertible preferred stock and a five-year warrant to purchase one share of common stock with an exercise price of $1.15 per share.

  • Salarius Pharmaceuticals to Present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference
    GlobeNewswire

    Salarius Pharmaceuticals to Present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference (NobleCon 16) being held February 16-18, 2020 in Hollywood, FL. During the presentation, Mr. Arthur will highlight recent corporate achievements and the upcoming milestones for Salarius’ clinical development pipeline.

  • Salarius Announces Pricing of $9.6 Million Underwritten Public Offering
    GlobeNewswire

    Salarius Announces Pricing of $9.6 Million Underwritten Public Offering

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $9.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius. The offering is comprised of 7,101,307 Class A Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $1.15 per share, and 1,246,519 Class B Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of Series A convertible preferred stock and a five-year warrant to purchase one share of common stock with an exercise price of $1.15 per share.

  • Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference
    GlobeNewswire

    Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the BIO CEO & Investor Conference being held February 10-11, 2020 in New York City. During the presentation, Mr. Arthur will highlight recent corporate achievements and the upcoming milestones for Salarius’ clinical development pipeline. Salarius’ lead compound, Seclidemstat, is a potent reversible inhibitor of the LSD1 enzyme.

  • Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors
    GlobeNewswire

    Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, today announced the publication of a scientific paper entitled, “The Novel Reversible LSD1 Inhibitor SP-2577 Promotes Anti-Tumor Immunity in SWItch/Sucrose-NonFermentable (SWI/SNF)1,” available in preprint at bioRxiv.com. The paper highlights data from in vitro studies conducted by Sunil Sharma, M.D., Salarius’ scientific founder, and his team at the Translational Genomic Institute (TGen) in Phoenix, AZ that demonstrate the potential for SP-2577, also known as Seclidemstat, Salarius’ lead clinical drug candidate, to be used in combination with checkpoint inhibitors to treat cancers with identifiable (i.e., SWI/SNF) mutations.

  • Salarius Pharmaceuticals to Present at Biotech Showcase 2020
    GlobeNewswire

    Salarius Pharmaceuticals to Present at Biotech Showcase 2020

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics, announced today that its chief executive officer, David Arthur, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California. During the presentation, Mr. Arthur will highlight recent corporate achievements and anticipated milestones from its clinical development pipeline, which is led by Seclidemstat, a potent reversible inhibitor of the LSD1 enzyme. Seclidemstat is currently the subject of an ongoing Phase 1/2 clinical trial in Ewing sarcoma, a rare and deadly pediatric bone cancer for which there is no approved targeted treatment.

  • Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression
    GlobeNewswire

    Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will host a key opinion leader (KOL) call on Epigenetics, Thursday, December 19th at 12pm Eastern Time. The call will feature a presentation by KOLs Damon Reed, MD, Moffitt Cancer Center, and Johnathan Whetstine, PhD, Fox Chase Cancer Center, who will discuss Epigenetics, and how drugs that regulate gene expression (“epigenetic drugs”) are a viable strategy for treatment and management of cancer.

  • Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma
    GlobeNewswire

    Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its lead investigational drug candidate, Seclidemstat, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Ewing sarcoma who have relapsed or are refractory to standard-of-care therapy. Seclidemstat, a potent reversible LSD1 inhibitor, is the subject of an ongoing Phase 1/2 clinical study in Ewing sarcoma.

  • Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic
    GlobeNewswire

    Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

    Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, announced today the acceptance of an abstract at the “Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic” taking place Monday, December 16, 2019 at the Franklin Institute in Philadelphia, PA. The trial-in-progress poster presentation will include an overview of the ongoing Phase 1/2 clinical trial for Salarius’ lead drug candidate, Seclidemstat, a potent reversible LSD1 inhibitor being developed as a treatment for Ewing sarcoma, a rare pediatric bone cancer.

  • Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results
    GlobeNewswire

    Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

    HOUSTON, Nov. 13, 2019 -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting the epigenetic causes of cancer, today reported its.

  • Houston pharma co. lands nearly $11M investment from Chicago group
    American City Business Journals

    Houston pharma co. lands nearly $11M investment from Chicago group

    Because of the investment, the Houston pharmaceutical company has additional capital to advance its cancer drug through clinical trials.

  • Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement
    GlobeNewswire

    Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it has entered into a $10.9 million common stock purchase agreement, including a $1.0 million initial common stock purchase, with Aspire Capital Fund, LLC, a Chicago-based institutional investor. With the investment by Aspire plus non-dilutive funding from the Cancer Prevention Research Institute of Texas (CPRIT) and ongoing financial support from the National Pediatric Cancer Foundation, Salarius believes it is well-capitalized to advance its current clinical programs through a number of near-term, value creating milestones, including early safety and efficacy data readouts from the ongoing Phase 1/2 clinical trial of Seclidemstat, Salarius’ lead drug candidate, in Ewing sarcoma and the Phase 1 clinical trial of Seclidemstat in advanced solid tumors.

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference Lineup October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences
    GlobeNewswire

    Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced its participation at two upcoming investor conferences. On October 17, 2019, management will participate in a panel at the Oppenheimer Oncology Summit in Houston, TX. Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most.

  • Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma
    GlobeNewswire

    Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced today that Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Nationwide Children’s Hospital (Nationwide Children’s) in Columbus, OH have been added as clinical trial sites in the ongoing Phase 1/2 clinical trial of Seclidemstat for the treatment of Ewing sarcoma.  The addition of MSKCC and Nationwide Children’s brings the total number of active clinical trial sites to eight.

  • Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials
    GlobeNewswire

    Salarius Pharmaceuticals Achieves Dose-Escalation Milestones in Ongoing Phase 1/2 Ewing Sarcoma and Phase 1 Advanced Solid Tumor Clinical Trials

    The Phase 1/2 clinical trial of Seclidemstat in Ewing sarcoma and Phase 1 AST clinical trial are designed as open-label dose-finding studies to determine the maximum tolerated dose (MTD) and initial safety profile of Seclidemstat.  Seclidemstat is administered daily as an oral tablet, with each cohort receiving an increased dose of study medication. This MTD, as determined by the Safety Review Committee, will then be used to treat a larger group of patients to confirm the safety profile for Seclidemstat and capture additional information regarding pharmacokinetics and potential preliminary efficacy.

  • Salarius Pharmaceuticals Announces Senior Leadership Changes
    GlobeNewswire

    Salarius Pharmaceuticals Announces Senior Leadership Changes

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment of Scott Jordan to the new role of Chief Business Officer and the appointment of Mark Rosenblum to the position of Executive Vice President Finance and Interim Chief Financial Officer.

  • Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month
    GlobeNewswire

    Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for Childhood Cancer Awareness Month, designated as the month of September. Recognizing the work underway by the National Pediatric Cancer Foundation and the many other organizations, foundations and associations around the world to raise awareness of childhood cancers, Salarius joins with these groups in exploring targeted treatments for children and their families seeking new therapeutic options. According to data from the U.S. Centers for Disease Control and Prevention, approximately 15,000 U.S. children and adolescents younger than 20 years will receive a cancer diagnosis each year.  In the past 40 years, less than 10 drugs have been developed for use in children with cancer, a number that pales in comparison to the hundreds developed for adult cancers.  Despite improvements in overall survival rates, survival rates for some types of childhood cancer remain discouragingly low, and some childhood and adolescent cancer survivors often face long-term complications, including heart disease, infertility or secondary cancers related to their treatment.

  • Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma
    GlobeNewswire

    Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma

    The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat, for the treatment of glioblastoma. It is currently being tested by Salarius in a Phase 1 study for refractory or relapsed Ewing’s sarcoma and a Phase 1 study for Advanced Solid Tumors. Seclidemstat is among the most clinically advanced reversible LSD1 inhibitors in development, and its potential effect on glioblastoma represents a promising new therapeutic treatment option.

  • Salarius Pharmaceuticals CEO Issues Letter to Stockholders
    GlobeNewswire

    Salarius Pharmaceuticals CEO Issues Letter to Stockholders

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that its chief executive officer, David Arthur, issued an open letter to Salarius’ stockholders following the completion of the reverse merger with Flex Pharma, Inc. The following letter can also be viewed on Salarius’ website. Following the reverse merger, Salarius’ stockholder base is now comprised of a combination of former Flex Pharma stockholders, former unit holders of Salarius Pharmaceuticals, LLC, and new stockholders. The purpose of this letter is to provide each of you with an overview and update on Salarius Pharmaceuticals, Inc. and our plan for building stockholder value by advancing clinical programs.

  • Can We See Significant Insider Ownership On The Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Share Register?
    Simply Wall St.

    Can We See Significant Insider Ownership On The Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Share Register?

    A look at the shareholders of Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) can tell us which group is most powerful...

  • Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell
    GlobeNewswire

    Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell

    Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that President and Chief Executive Officer David Arthur and other members of the management team, will ring the Nasdaq Opening Bell on Tuesday, July 30, 2019. The Opening Bell ceremony will be broadcast live starting at 9:15am Eastern Time from the Nasdaq MarketSite Tower in New York City. David Arthur, President and CEO of Salarius Pharmaceuticals, stated, “This is a great day for Salarius, and it is our honor to ring the Nasdaq Opening Bell commemorating our recent public listing.